Andarine (formerly known as GTx-007; S-4; GTx007; S4) is an orally bioactive and selective non-steroidal androgen receptor (AR) agonist, specifically a selective androgen receptor modulator (SARM), that has potential usefulness in muscle wasting and osteoporosis.

Dimethylcurcumin (formerly known as ASC-J9; GO-Y025) is an androgen receptor (AR) degradation enhancer that effectively suppresses castration resistant prostate cancer cell proliferation and invasion.

Ostarine (aslo known as Enobosarm, GTx024, MK2866, GTx-024, MK-2866) is a novel, potent and selective androgen receptor modulator (SARM) with potential antitumor activity..

Cyproterone acetate (Cyprone, Androcur, Cyprostat,Cyprohexal, Ciproterona, Cyproteron, Procur, Cyproteronum, Neoproxil, Siterone), an analog of 17-hydroxyprogesterone, is an androgen receptor (AR) antagonist with potential antitumor activity.

TRC-253, also known as JNJ-63576253, is a novel,potent and orally active androgen receptor antagonist.

GSK 2881078 (GSK2881078) is a novel, potent and selective androgen receptor modulator (SARM) that can be potentially used for the treatment of cachexia.

Bavdegalutamide (ARV110; ARV-110) is an orally bioavailable PROTAC-based Androgen Receptor (AR) degrader with potential anticancer activity.

N-desmethyl Enzalutamide (N-desmethyl MDV 3100) is an active metabolite of Enzalutamide which is is a novel, potent, orally bioavailable, organic, non-steroidal small molecule, second-generation androgen-receptor (AR) antagonist.

Bicalutamide (formerly known as ICI-176334; CDX; trade names: Casodex in the USA and Cosudex in other countries), a marketed drug for treating PC (prostate cancer), is a potent, synthetic, nonsteroidal androgen receptor (AR) antagonist with potential anticancer activity.

UT-34 (UT34) is a novel, selective, and orally bioavailable pan-androgen receptor (AR) antagonist and also a selective androgen receptor degrader (SARD) with anti-prostate cancer activity.